193 related articles for article (PubMed ID: 36291153)
1. Intracellular Metabolomics Identifies Efflux Transporter Inhibitors in a Routine Caco-2 Cell Permeability Assay-Biological Implications.
Naseem A; Pal A; Gowan S; Asad Y; Donovan A; Temesszentandrási-Ambrus C; Kis E; Gaborik Z; Bhalay G; Raynaud F
Cells; 2022 Oct; 11(20):. PubMed ID: 36291153
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance-associated protein 2 (MRP2) is an efflux transporter of EGCG and its metabolites in the human small intestine.
Kikuchi T; Hayashi A; Ikeda N; Morita O; Tasaki J
J Nutr Biochem; 2022 Sep; 107():109071. PubMed ID: 35636688
[TBL] [Abstract][Full Text] [Related]
3. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
4. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
6. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
7. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
8. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
9. Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2.
Bi X; Yuan Z; Qu B; Zhou H; Liu Z; Xie Y
Phytomedicine; 2019 Feb; 54():98-108. PubMed ID: 30668388
[TBL] [Abstract][Full Text] [Related]
10. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
11. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
[TBL] [Abstract][Full Text] [Related]
12. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
13. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
[TBL] [Abstract][Full Text] [Related]
14. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
15. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
[TBL] [Abstract][Full Text] [Related]
16. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
[TBL] [Abstract][Full Text] [Related]
18. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.
Anger GJ; Cressman AM; Piquette-Miller M
PLoS One; 2012; 7(4):e35027. PubMed ID: 22558111
[TBL] [Abstract][Full Text] [Related]
19. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
20. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein.
Gonçalves P; Gregório I; Martel F
Am J Physiol Cell Physiol; 2011 Nov; 301(5):C984-94. PubMed ID: 21775706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]